Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

Fred :.....it looks like a cure....99%...in mice...and now testing humans....in Switzerland trials....a system like this gets commercialised and the sky is the limit for this company......the big boys would want to buy this firm then.....

Link copied :- Biotech minnow Angle triumphs with cancer blood testing kit

More good news....could be a real winner this year, this company....

Had a few last week.

Looks promising.

£1 by xmas :-)